Eur Rev Med Pharmacol Sci 2019; 23 (3 Suppl): 232-238

DOI: 10.26355/eurrev_201908_18652

LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer

X.-Y. Shi, Y.-Z. Sun, M. Li, H.-Y. Li

Department of Laboratory Medicine, The Children and Women’s Healthcare of Laiwu City, Laiwu, China. 13864629818@163.com


OBJECTIVE: To investigate the expression of the long non-coding RNA CADM1-AS1 (lncRNA CADM1-AS1) in gastric cancer and its clinical significance.

PATIENTS AND METHODS: The real time fluorescence quantitative polymerase chain reaction (qRT-PCR) was performed to detect the expression difference of lncRNA CADM1-AS1 between gastric cancer and its adjacent normal tissues. Then, the correlation between the expression of CADM1-AS1 in gastric cancer and the clinicopathological characteristics was analyzed by the Chi-square test. Moreover, the potential of lncRNA CADM1-AS1 in predicting the prognosis of patients with GC after the operation was assessed by the Log-rank test and the Cox’s proportional hazards regression model.

RESULTS: The expression of lncRNA CADM1-AS1 was significantly decreased in tumor tissues. According to the mean expression of lncRNA CADM1-AS1, the patients were divided into a high expression group and a low expression group, and the expression of lncRNA CADM1-AS1 in gastric cancer was significantly correlated with tumor differentiation, N stage, M stage, and TNM stage. Moreover, the gastric cancer patients with higher expression of lncRNA CADM1-AS1 had a statistically better overall survival (OS) time and progression-free survival (PFS) time. In univariate analyses and multivariate analyses, the expression of lncRNA CADM1-AS1 was an independent prognosis index of patients with gastric cancer.

CONCLUSIONS: LncRNA CADM1-AS1 might be a new prognostic biomarker for gastric cancer.

Free PDF Download

To cite this article

X.-Y. Shi, Y.-Z. Sun, M. Li, H.-Y. Li
LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 3 Suppl
Pages: 232-238
DOI: 10.26355/eurrev_201908_18652